(NASDAQ: RIGL) Rigel Pharmaceuticals's forecast annual revenue growth rate of 6.45% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.99%.
Rigel Pharmaceuticals's revenue in 2026 is $299,767,000.On average, 7 Wall Street analysts forecast RIGL's revenue for 2026 to be $5,293,630,109, with the lowest RIGL revenue forecast at $5,055,138,298, and the highest RIGL revenue forecast at $5,486,421,782. On average, 7 Wall Street analysts forecast RIGL's revenue for 2027 to be $6,000,039,523, with the lowest RIGL revenue forecast at $5,563,390,435, and the highest RIGL revenue forecast at $6,692,757,398.
In 2028, RIGL is forecast to generate $6,690,722,170 in revenue, with the lowest revenue forecast at $5,985,422,880 and the highest revenue forecast at $8,237,126,016.